Meitav Dash Investments Ltd. cut its stake in shares of Orthopediatrics Corp (NASDAQ:KIDS) by 47.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,270 shares of the company’s stock after selling 19,000 shares during the quarter. Meitav Dash Investments Ltd. owned approximately 0.14% of Orthopediatrics worth $941,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. RTW Investments LP bought a new position in shares of Orthopediatrics in the fourth quarter valued at about $7,848,000. Prospect Capital Advisors LLC bought a new stake in Orthopediatrics during the 4th quarter worth about $7,136,000. American Century Companies Inc. bought a new stake in Orthopediatrics during the 4th quarter worth about $3,880,000. BlackRock Inc. raised its holdings in Orthopediatrics by 12.4% during the 4th quarter. BlackRock Inc. now owns 455,657 shares of the company’s stock worth $15,894,000 after purchasing an additional 50,179 shares during the last quarter. Finally, FMR LLC raised its holdings in Orthopediatrics by 8.6% during the 4th quarter. FMR LLC now owns 414,600 shares of the company’s stock worth $14,462,000 after purchasing an additional 33,000 shares during the last quarter. 48.67% of the stock is owned by institutional investors.
Several equities analysts have recently issued reports on the company. BidaskClub lowered Orthopediatrics from a “buy” rating to a “hold” rating in a research report on Monday, June 24th. Needham & Company LLC assumed coverage on Orthopediatrics in a research report on Wednesday, June 19th. They set a “buy” rating and a $53.00 target price for the company. Zacks Investment Research lowered Orthopediatrics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 14th. Finally, BTIG Research reiterated a “buy” rating and issued a $44.00 price objective on shares of Orthopediatrics in a research report on Friday, May 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $43.40.
Orthopediatrics (NASDAQ:KIDS) last released its earnings results on Wednesday, May 8th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.04). Orthopediatrics had a negative net margin of 16.71% and a negative return on equity of 16.43%. The firm had revenue of $14.66 million during the quarter, compared to the consensus estimate of $14.67 million. Sell-side analysts expect that Orthopediatrics Corp will post -0.45 EPS for the current year.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Further Reading: Compound Interest and Why It Matters When Investing
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.